Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Oral MG001 in Healthy Volunteers
NCT07204171Phase 1Not yet recruiting
- Sponsor
- National Institute on Drug Abuse
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mitragynine in opioid withdrawal (5 arms), sponsored by National Institute on Drug Abuse. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at Day 7. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mitragynine
03
Conditions
opioid withdrawal
Beyond the preview
Go deeper on NCT07204171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204171.